

26 Apr 2024 | Analysis

China Biotech Podcast: AACR, BIOSECURE European Perspectives

by Brian Yang

Guest Andrew McConaghie from *Scrip*'s UK team joins Brian Yang and Dexter Yan to discuss AACR highlights from Chinese biotechs, European perspectives on the proposed US BIOSECURE Act, two recent acquisitions and Boehringer Ingelheim's recent quarterly results.

Brian Yang, Dexter Yan, Citeline, Andrew Cognahie

AACR, Dexter, AACR, AACR, III, garsorasib, D-1553, II

Scrip, Andrew McConaghie, Biosecure, ProfoundBio, Genmab, Anheart Nuvation, perspective

Andrew, Sino Biopharma, BI

Join China-based *Scrip* editors Brian Yang and Dexter Yan as they look at some of the highlights from Chinese biotechs presenting clinical results at this year's annual meeting of the American Association for Cancer Research (AACR). Multiple companies including [Akeso Inc.](#) brought their latest data to the San Diego meeting, what were some of the most notable points?

UK-based *Scrip* senior writer Andrew McConaghie also joins the discussion to help understand two recent acquisitions involving Chinese firms, that of [ProfoundBio \(Suzhou\) Co., Ltd.](#) by [Genmab](#)

[A/S](#) and of [AnHeart Therapeutics](#) by [Nuvation Bio, Inc.](#)

Andrew also discusses [Boehringer Ingelheim GmbH](#)'s latest quarterly results and provides additional perspectives from Europe on the proposed US BIOSECURE Act.

Stories discussed in this podcast:

(Also see "[AACR: Akeso's Cadonilimab Shows 1L Potential In Adenocarcinoma](#)" - Scrip, 9 Apr, 2024.)

(Also see "[BIOSECURE: What's Coming Next?](#)" - Pink Sheet, 10 Apr, 2024.)

(Also see "[Boehringer Ingelheim Overtakes Bayer As Germany's Biggest Pharma Company](#)" - Scrip, 16 Apr, 2024.)

[Click here to explore this interactive content online](#) 